贤丰控股(002141) - 2023 Q2 - 季度财报(更正)

Financial Performance - The company's operating revenue for the first half of 2023 was ¥44,500,982.34, a decrease of 92.56% compared to the same period last year[2] - The net profit attributable to shareholders was -¥23,690,175.34, marking a 201.30% decline year-over-year[2] - The net cash flow from operating activities was -¥38,296,134.46, a decrease of 44.02% compared to the previous year[3] - The basic and diluted earnings per share were both -¥0.0209, a decline of 201.46% from the previous year[3] - The total assets at the end of the reporting period were ¥1,300,432,707.06, down 3.19% from the end of the previous year[3] Business Segments - The company’s main business is focused on veterinary vaccines, with a significant impact from the downturn in the pig farming industry, leading to intensified price competition[8] - The revenue from the subsidiary Shiji Biological for the first half of 2023 was ¥34,378,900, an increase of 16.97% year-over-year, while the net profit was -¥4,299,200, indicating a reduced loss compared to the previous year[9] - The lithium-ion battery precursor business faced challenges, with insufficient orders and operational losses, while the industrial-grade lithium carbonate project is progressing slower than expected[9] Strategic Outlook - The strategic transition of the company remains stable, seeking breakthroughs despite the operational losses primarily due to the underperformance of the lithium-ion battery business and increased financial costs[10] - The company plans not to distribute cash dividends or issue new shares from reserves for this reporting period[1] Growth and Development - The company reported a significant increase in revenue for the first half of 2023, achieving a total of 1.2 billion RMB, representing a 15% year-over-year growth[12] - User data indicates a growth in active users, reaching 5 million, which is a 20% increase compared to the previous year[12] - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 12%[12] - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of the year[12] - The company is investing in new technology development, allocating 100 million RMB towards R&D initiatives[12] - Market expansion efforts have led to a 30% increase in market share in the Southeast Asia region[12] - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB earmarked for this purpose[12] - A new strategic partnership has been established, expected to generate an additional 150 million RMB in revenue over the next year[12] - The gross margin for the first half of 2023 improved to 45%, up from 42% in the same period last year[12] - Operating expenses have been reduced by 5%, contributing to overall profitability improvements[12]